Comprehensive effect of Naoxintong capsule combined with Western medicine on coronary heart disease after percutaneous coronary intervention: a meta-analysis
Aims:To systematically evaluate the comprehensive effect of combining Naoxintong capsule (NXT) with Western medicine (WM) on coronary heart disease post-percutaneous coronary intervention (PCI).Methods:Randomized controlled trials (RCTs) of NXT for patients with CHD after PCI were systematically sea...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1274000/full |
| _version_ | 1827309562332446720 |
|---|---|
| author | Liyuan Yu Liyuan Yu Peiying Huang Peiying Huang Meida Wang Meida Wang Zhishang Li Zhishang Li Hairong Cai Hairong Cai Yuchao Feng Yuchao Feng Lulu Wu Lulu Wu Weihang Peng Weihang Peng Jing Zeng Jing Zeng Bojun Chen Bojun Chen Bojun Chen |
| author_facet | Liyuan Yu Liyuan Yu Peiying Huang Peiying Huang Meida Wang Meida Wang Zhishang Li Zhishang Li Hairong Cai Hairong Cai Yuchao Feng Yuchao Feng Lulu Wu Lulu Wu Weihang Peng Weihang Peng Jing Zeng Jing Zeng Bojun Chen Bojun Chen Bojun Chen |
| author_sort | Liyuan Yu |
| collection | DOAJ |
| description | Aims:To systematically evaluate the comprehensive effect of combining Naoxintong capsule (NXT) with Western medicine (WM) on coronary heart disease post-percutaneous coronary intervention (PCI).Methods:Randomized controlled trials (RCTs) of NXT for patients with CHD after PCI were systematically searched across multiple databases, including the Cochrane Library, PubMed, Embase, Chinese National Knowledge Infrastructure (CNKI), Chinese Science and Technology Journal Database (VIP), and Wan Fang, from inception until 31 January 2023. Study selection, data extraction, and quality assessment were performed by two independent reviewers. The quality of the included studies was evaluated using version 2 of the Cochrane risk-of-bias tool (RoB 2), and data analysis was performed using R4.2.2.Results:Fifteen RCTs conducted between 2011 and 2022 and involving 1,551 patients were identified, with 774 and 777 patients in the experimental and control groups respectively. It was found that the NXT and WM combination was superior to the WM therapy alone in terms of the effective clinical rate (odds ratio [OR] = 4.69, 95% confidence interval [CI] = 2.13–10.30), effective rate in electrocardiogram (OR = 6.92, 95% CI = 3.44–13.92), effective rate in angina (OR = 5.90, 95% CI = 3.04–11.46), left ventricular ejection fraction (mean difference [MD] = 4.94, 95% CI = 2.89–6.99), brain natriuretic peptide (MD = −294.00, 95% CI = −584.60 to −3.39), creatine kinase-MB (MD = −7.82, 95% CI = −13.26 to −2.37), major adverse cardiovascular events (OR = 0.24, 95% CI = 0.14–0.43), maximum platelet aggregation rate (MD = −8.33, 95% CI = −11.64 to −5.01), and Chinese medicine evidence score (OR = 9.79, 95% CI = 3.57–26.85). However, there was no significant difference in cardiac troponin I level reduction (MD = −0.13, 95% CI = 0.35–0.09) or the occurrence of adverse medicine events (OR = 0.92, 95% CI = 0.41–2.05). Meta-regression and subgroup analyses indicated that NXT capsule dosage, treatment duration, and patient baseline characteristics contributed to the heterogeneity.Conclusion:A combination of NXT and WM can improve clinical outcomes in patients undergoing PCI. However, further studies are needed to confirm the reliability and safety of this combined treatment approach.Systematic Review Registration:PROSPERO, https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=369174, Identifier CRD42022369174. |
| first_indexed | 2024-04-24T19:44:30Z |
| format | Article |
| id | doaj.art-c4145bb947474f57935e0366759692c3 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-24T19:44:30Z |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-c4145bb947474f57935e0366759692c32024-03-25T09:58:37ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-03-011510.3389/fphar.2024.12740001274000Comprehensive effect of Naoxintong capsule combined with Western medicine on coronary heart disease after percutaneous coronary intervention: a meta-analysisLiyuan Yu0Liyuan Yu1Peiying Huang2Peiying Huang3Meida Wang4Meida Wang5Zhishang Li6Zhishang Li7Hairong Cai8Hairong Cai9Yuchao Feng10Yuchao Feng11Lulu Wu12Lulu Wu13Weihang Peng14Weihang Peng15Jing Zeng16Jing Zeng17Bojun Chen18Bojun Chen19Bojun Chen20The Second Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Research on Emergency in Traditional Chinese Medicine, Clinical Research Team of Prevention and Treatment of Cardiac Emergencies with Traditional Chinese Medicine, Guangzhou, ChinaThe Second Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Research on Emergency in Traditional Chinese Medicine, Clinical Research Team of Prevention and Treatment of Cardiac Emergencies with Traditional Chinese Medicine, Guangzhou, ChinaThe Second Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Research on Emergency in Traditional Chinese Medicine, Clinical Research Team of Prevention and Treatment of Cardiac Emergencies with Traditional Chinese Medicine, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Research on Emergency in Traditional Chinese Medicine, Clinical Research Team of Prevention and Treatment of Cardiac Emergencies with Traditional Chinese Medicine, Guangzhou, ChinaEmergency Department of Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Research on Emergency in Traditional Chinese Medicine, Clinical Research Team of Prevention and Treatment of Cardiac Emergencies with Traditional Chinese Medicine, Guangzhou, ChinaEmergency Department of Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Research on Emergency in Traditional Chinese Medicine, Clinical Research Team of Prevention and Treatment of Cardiac Emergencies with Traditional Chinese Medicine, Guangzhou, ChinaEmergency Department of Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, ChinaThe Second Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Research on Emergency in Traditional Chinese Medicine, Clinical Research Team of Prevention and Treatment of Cardiac Emergencies with Traditional Chinese Medicine, Guangzhou, ChinaThe Second Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Research on Emergency in Traditional Chinese Medicine, Clinical Research Team of Prevention and Treatment of Cardiac Emergencies with Traditional Chinese Medicine, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Research on Emergency in Traditional Chinese Medicine, Clinical Research Team of Prevention and Treatment of Cardiac Emergencies with Traditional Chinese Medicine, Guangzhou, ChinaEmergency Department of Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, ChinaThe Second Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Research on Emergency in Traditional Chinese Medicine, Clinical Research Team of Prevention and Treatment of Cardiac Emergencies with Traditional Chinese Medicine, Guangzhou, ChinaEmergency Department of Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, ChinaAims:To systematically evaluate the comprehensive effect of combining Naoxintong capsule (NXT) with Western medicine (WM) on coronary heart disease post-percutaneous coronary intervention (PCI).Methods:Randomized controlled trials (RCTs) of NXT for patients with CHD after PCI were systematically searched across multiple databases, including the Cochrane Library, PubMed, Embase, Chinese National Knowledge Infrastructure (CNKI), Chinese Science and Technology Journal Database (VIP), and Wan Fang, from inception until 31 January 2023. Study selection, data extraction, and quality assessment were performed by two independent reviewers. The quality of the included studies was evaluated using version 2 of the Cochrane risk-of-bias tool (RoB 2), and data analysis was performed using R4.2.2.Results:Fifteen RCTs conducted between 2011 and 2022 and involving 1,551 patients were identified, with 774 and 777 patients in the experimental and control groups respectively. It was found that the NXT and WM combination was superior to the WM therapy alone in terms of the effective clinical rate (odds ratio [OR] = 4.69, 95% confidence interval [CI] = 2.13–10.30), effective rate in electrocardiogram (OR = 6.92, 95% CI = 3.44–13.92), effective rate in angina (OR = 5.90, 95% CI = 3.04–11.46), left ventricular ejection fraction (mean difference [MD] = 4.94, 95% CI = 2.89–6.99), brain natriuretic peptide (MD = −294.00, 95% CI = −584.60 to −3.39), creatine kinase-MB (MD = −7.82, 95% CI = −13.26 to −2.37), major adverse cardiovascular events (OR = 0.24, 95% CI = 0.14–0.43), maximum platelet aggregation rate (MD = −8.33, 95% CI = −11.64 to −5.01), and Chinese medicine evidence score (OR = 9.79, 95% CI = 3.57–26.85). However, there was no significant difference in cardiac troponin I level reduction (MD = −0.13, 95% CI = 0.35–0.09) or the occurrence of adverse medicine events (OR = 0.92, 95% CI = 0.41–2.05). Meta-regression and subgroup analyses indicated that NXT capsule dosage, treatment duration, and patient baseline characteristics contributed to the heterogeneity.Conclusion:A combination of NXT and WM can improve clinical outcomes in patients undergoing PCI. However, further studies are needed to confirm the reliability and safety of this combined treatment approach.Systematic Review Registration:PROSPERO, https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=369174, Identifier CRD42022369174.https://www.frontiersin.org/articles/10.3389/fphar.2024.1274000/fullcoronary heart diseasepercutaneous coronary interventionNaoxintong capsuleefficacysafetymeta-analysis |
| spellingShingle | Liyuan Yu Liyuan Yu Peiying Huang Peiying Huang Meida Wang Meida Wang Zhishang Li Zhishang Li Hairong Cai Hairong Cai Yuchao Feng Yuchao Feng Lulu Wu Lulu Wu Weihang Peng Weihang Peng Jing Zeng Jing Zeng Bojun Chen Bojun Chen Bojun Chen Comprehensive effect of Naoxintong capsule combined with Western medicine on coronary heart disease after percutaneous coronary intervention: a meta-analysis Frontiers in Pharmacology coronary heart disease percutaneous coronary intervention Naoxintong capsule efficacy safety meta-analysis |
| title | Comprehensive effect of Naoxintong capsule combined with Western medicine on coronary heart disease after percutaneous coronary intervention: a meta-analysis |
| title_full | Comprehensive effect of Naoxintong capsule combined with Western medicine on coronary heart disease after percutaneous coronary intervention: a meta-analysis |
| title_fullStr | Comprehensive effect of Naoxintong capsule combined with Western medicine on coronary heart disease after percutaneous coronary intervention: a meta-analysis |
| title_full_unstemmed | Comprehensive effect of Naoxintong capsule combined with Western medicine on coronary heart disease after percutaneous coronary intervention: a meta-analysis |
| title_short | Comprehensive effect of Naoxintong capsule combined with Western medicine on coronary heart disease after percutaneous coronary intervention: a meta-analysis |
| title_sort | comprehensive effect of naoxintong capsule combined with western medicine on coronary heart disease after percutaneous coronary intervention a meta analysis |
| topic | coronary heart disease percutaneous coronary intervention Naoxintong capsule efficacy safety meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1274000/full |
| work_keys_str_mv | AT liyuanyu comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT liyuanyu comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT peiyinghuang comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT peiyinghuang comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT meidawang comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT meidawang comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT zhishangli comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT zhishangli comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT hairongcai comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT hairongcai comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT yuchaofeng comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT yuchaofeng comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT luluwu comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT luluwu comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT weihangpeng comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT weihangpeng comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT jingzeng comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT jingzeng comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT bojunchen comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT bojunchen comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis AT bojunchen comprehensiveeffectofnaoxintongcapsulecombinedwithwesternmedicineoncoronaryheartdiseaseafterpercutaneouscoronaryinterventionametaanalysis |